Le Lézard
Classified in: Health
Subject: PSF

BioDelivery Sciences Participates in U.S. Department of Health and Human Services Round Table Discussion on Pain Management and Opioid Dependence



RALEIGH, N.C., Oct. 6, 2017 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) participated in a round table meeting convened this week in Washington, D.C. by the U.S. Department of Health and Human Services (HHS) to discuss efforts to advance pain management therapies and the treatment of opioid dependence as well as advancing alternative therapies. BDSI was represented by its Vice Chairman, President and Chief Executive Officer, Dr. Mark A. Sirgo, who discussed BDSI's work to develop novel products, such as buprenorphine, for the treatment of chronic pain and opioid dependence.

BDSI Logo. (PRNewsFoto/BioDelivery Sciences International, Inc.)

"I was pleased to participate in this important discussion convened by HHS, and we appreciate the opportunity to share the work BDSI is doing to advance effective pain management therapies and the treatment of opioid dependence in light of the current opioid epidemic we face," said Dr. Sirgo.  "BDSI has been focused on bringing healthcare providers alternative formulations of buprenorphine based on knowledge that it provides an effective, Schedule III alternative to other more addictive opioids.  We recognize the seriousness of the conversation about opioids and their role in pain management in this country and the need to continue to provide and develop effective and safer options for the nearly 100 million Americans who currently suffer from chronic pain as well as those needing support to address their addiction to opioids, and we are pleased to provide products that can be part of the solution."

During the round table discussion Dr. Sirgo introduced BDSI, highlighted its innovative drug delivery technology and products, and expressed the company's mission to develop therapies to treat pain as well as opioid dependence.

About BioDelivery Sciences International

BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is a specialty pharmaceutical company with a focus in the areas of pain management and addiction medicine.  BDSI is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs.

BDSI's marketed products and those in development address serious and debilitating conditions such as breakthrough cancer pain, chronic pain and opioid dependence.  BDSI's headquarters is in Raleigh, North Carolina.  

For more information, please visit or follow us:

Internet:             

www.bdsi.com

Facebook:          

Facebook.com/BioDeliverySI

Twitter:                

@BioDeliverySI

BUNAVAIL® (buprenorphine and naloxone) buccal film (CIII) and BELBUCA® (buprenorphine) buccal film (CIII) are marketed in the U.S. by BioDelivery Sciences.   ONSOLIS® (fentanyl buccal soluble film) (CII) is licensed in the U.S. to Collegium Pharmaceutical pursuant to the U.S. licensing and development agreement between BDSI and Collegium. For full prescribing information and important safety information on BDSI products, including BOXED WARNINGS for ONSOLIS, please visit www.bdsi.com where the Company promptly posts press releases, SEC filings and other important information or contact the Company at (800) 469-0261.  For full prescribing and safety information on BELBUCA, please visit www.belbuca.com and for full prescribing and safety information on BUNAVAIL, please visit www.bunavail.com.

Cautionary Note on Forward-Looking Statements

This press release, the presentations described herein, and any statements of employees, representatives and partners of BioDelivery Sciences International, Inc. (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  Such forward-looking statements involve significant risks and uncertainties.  Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions.  These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission.  Actual results (including, without limitation, the results of the Company's commercialization programs for BELBUCA and BUNAVAIL) may differ significantly from those set forth or implied in the forward-looking statements.  These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control).  The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.

BDSI®, BEMA®, ONSOLIS®, BUNAVAIL® and BELBUCA® are registered trademarks of BioDelivery Sciences International, Inc.  The BioDelivery Sciences, BUNAVAIL and BELBUCA logos are trademarks owned by BioDelivery Sciences International, Inc.  All other trademarks and tradenames are owned by their respective owners.

© 2017 BioDelivery Sciences International, Inc.  All rights reserved.

SOURCE BioDelivery Sciences International, Inc.


These press releases may also interest you

at 12:03
BioSyent Inc. ("BioSyent") is pleased to announce that it will be presenting at the following upcoming investor conferences: May 2, 2018 - Bloom Burton & Co. Healthcare Investor Conference at the Sheraton Centre Hotel Toronto, Toronto, Ontario. ...

at 12:01
Fresenius Kidney Care, a division of Fresenius Medical Care North America and the nation's leading network of dialysis facilities, announced today that it has achieved the highest results in the industry as part of the government's Five-Star Quality...

at 12:01
Today, Rich Baer was appointed Chair of the National Jewish Health Board of Directors. He succeeds Blair Richardson, who has been board chair for the past two years and will continue to serve on the Executive Committee of the Board....

at 12:01
As a new business partner to the National Association of ACOs (NAACOs), MobileHelp® Healthcare, a leader in personal and enterprise healthcare technology, will be displaying new chronic care solutions at Table #7 at the NAACOs spring conference this...

at 12:00
The "Global CRISPR Technology Market - Focus on Product, Applications, Geographical Analysis, Industry Insights and Competitive Landscape - Analysis and Forecast (2018-2027)" report has been added to ResearchAndMarkets.com's offering. The answers...

at 11:51
Anesthesia Business Consultants (ABC), a leading provider in billing and practice management for the anesthesia and pain management specialty, is pleased to announce they will be exhibiting and attending the Advanced Institute for Anesthesia Practice...




News published on 6 october 2017 at 07:00 and distributed by: